NRSN
NeuroSense Therapeutics Ltd. (NASDAQ)
Healthcare — Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Price History
Fundamentals
| Market Cap | $26.10M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.88 |
| EPS (TTM) | $-0.44 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -2174.98% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $6.50 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 48.6 |
| Beta | 1.54 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.19 |
| 52-Week Low | $0.63 |
| 50-Day Avg | $0.79 |
| 200-Day Avg | $0.93 |
| Avg Volume | 164.6K |
| Volume | 91.3K |
Performance Analysis
BULLISHNRSN shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report